Overview

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Status:
NOT_YET_RECRUITING
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.
Phase:
PHASE2
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
Angiotensin Receptor Antagonists
Antihypertensive Agents
fezolinetant
Metformin
semaglutide